237 related articles for article (PubMed ID: 25977342)
1. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-β1 gene expression in hepatocellular carcinoma: a preliminary report.
Farid IM; Hamza IM; El-Abd DM; Mohyi AM; AbdulLatif MM; Aref AT; Hamza DM
Arab J Gastroenterol; 2014; 15(3-4):142-7. PubMed ID: 25475758
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Lim S; Han J; Kim GM; Han KH; Choi HJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1024-31. PubMed ID: 25611175
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
[TBL] [Abstract][Full Text] [Related]
7. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
8. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
9. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Fransvea E; Angelotti U; Antonaci S; Giannelli G
Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
[TBL] [Abstract][Full Text] [Related]
10. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients.
Ibrahim GH; Mahmoud MA; Aly NM
Mol Biol Rep; 2013 Dec; 40(12):7069-75. PubMed ID: 24186850
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Shao YY; Huang CC; Lin SD; Hsu CH; Cheng AL
Clin Cancer Res; 2012 Jul; 18(14):3992-7. PubMed ID: 22623732
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
15. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
[No Abstract] [Full Text] [Related]
16. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
[TBL] [Abstract][Full Text] [Related]
18. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
Wei X; Tang C; Lu X; Liu R; Zhou M; He D; Zheng D; Sun C; Wu Z
Oncotarget; 2015 Jul; 6(21):18389-405. PubMed ID: 26158762
[TBL] [Abstract][Full Text] [Related]
19. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
20. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]